Radiosensitivity profiles from a panel of ovarian cancer cell lines exhibiting genetic alterations in p53 and disparate DNA-dependent protein kinase activities

被引:28
作者
Langland, Gregory T. [1 ]
Yannone, Steven M. [1 ]
Langland, Rachel A. [4 ]
Nakao, Aki [4 ]
Guan, Yinghui [1 ]
Long, Sydney B. T. [1 ]
Vonguyen, Lien [1 ]
Chen, David J. [5 ]
Gray, Joe W. [1 ,2 ,3 ]
Chen, Fanqing [1 ,2 ,3 ]
机构
[1] Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA
[2] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA
[4] Roche Mol Syst, Dept Pharmacogenet, Pleasanton, CA 94588 USA
[5] Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA
基金
中国国家自然科学基金;
关键词
ovarian cancer; non-homologous end joining; p53; p21; DNA-PK; DNA-PKcs; Ku; Ku70; Ku80; XRCC4; Ligase IV; radioresistance; radiosensitivity; apoptosis; double-strand break repair; microarray; comparative genomic hybridization; EXPRESSION; THERAPY; CARCINOMA; RADIATION; NECK; HEAD;
D O I
10.3892/or_00000728
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
The variability of radiation responses in ovarian tumors and tumor-derived cell lines is poorly understood. Since both DNA repair capacity and p53 Status call significantly alter radiation sensitivity, we evaluated these factors along with radiation sensitivity in a panel of sporadic human ovarian carcinoma cell lines. We observed a gradation of radiation sensitivity among these sixteen lines, with a five-fold difference in the LD(50) between the most radiosensitive and the most radioresistant cells. The DNA-dependent protein kinase (DNA-PK) is essential for the repair of radiation induced DNA double-strand breaks in human somatic cells. Therefore, we measured gene copy number, expression levels, protein abundance, genomic Copy and kinase activity for DNA-PK in all Of Our cell lines. While there were detectable differences in DNA-PK between the cell lines, there was no clear correlation with any of these differences and radiation sensitivity. In contrast, p53 function as determined by two independent methods, correlated well with radiation sensitivity, indicating p53 Mutant ovarian cancer cells are typically radioresistant relative to p53 wild-type lines. These data suggest that the activity of regulatory molecules Such as p53 may be better indicators of radiation sensitivity than DNA repair enzymes such as DNA-PK in ovarian cancer.
引用
收藏
页码:1021 / 1026
页数:6
相关论文
共 22 条
[1]
Ku70 predicts response and primary tumor recurrence after therapy in locally advanced head and neck cancer [J].
Angel Pavon, Miguel ;
Parreno, Matilde ;
Leon, Xavier ;
Sancho, Francesc J. ;
Virtudes Cespedes, Maria ;
Casanova, Isolda ;
Lopez-Pousa, Antonio ;
Antonia Mangues, Maria ;
Quer, Miquel ;
Barnadas, Agusti ;
Mangues, Ramon .
INTERNATIONAL JOURNAL OF CANCER, 2008, 123 (05) :1068-1079
[2]
Expression of Ku80 correlates with sensitivities to radiation in cancer cell lines of the head and neck [J].
Chang, Hyo Won ;
Kim, Sang Yoon ;
Yi, So-Lyoung ;
Son, Se-Hee ;
Song, Do Young ;
Moon, Su Young ;
Kim, Jong Hoon ;
Choi, Eun Kyung ;
Do Ahn, Seung ;
Shin, Seong Soo ;
Lee, Kang Kyoo ;
Lee, Sang-wook .
ORAL ONCOLOGY, 2006, 42 (10) :979-986
[3]
The life and death of DNA-PK [J].
Collis, SJ ;
DeWeese, TL ;
Jeggo, PA ;
Parker, AR .
ONCOGENE, 2005, 24 (06) :949-961
[4]
p53-dependent radioresistance in ovarian carcinoma cell lines [J].
Concin, N ;
Zeillinger, C ;
Stimpfel, M ;
Schiebel, I ;
Tong, D ;
Wolff, U ;
Reiner, A ;
Leodolter, S ;
Zeillinger, R .
CANCER LETTERS, 2000, 150 (02) :191-199
[5]
The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype [J].
Dicker, F. ;
Herholz, H. ;
Schnittger, S. ;
Nakao, A. ;
Patten, N. ;
Wu, L. ;
Kern, W. ;
Haferlach, T. ;
Haferlach, C. .
LEUKEMIA, 2009, 23 (01) :117-124
[6]
The role of p53 in chemosensitivity and radiosensitivity [J].
El-Deiry, WS .
ONCOGENE, 2003, 22 (47) :7486-7495
[7]
GALLION HH, 1995, CANCER, V76, P1992, DOI 10.1002/1097-0142(19951115)76:10+<1992::AID-CNCR2820761315>3.0.CO
[8]
2-U
[9]
George B, 2007, J CLIN ONCOL, V25, P5352, DOI 10.1200/JCO.2006.10.4125
[10]
Henkels KM, 1997, CANCER RES, V57, P4488